Ublituximab-话题@MedSci

#Ublituximab#

6篇内容 | 834人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2126636, encodeId=235f212663639, content=<a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a>加用<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a><a href='/topic/show?id=5cf21058993e' target=_blank style='color:#2F92EE;'>#乌妥昔单抗#</a>可显著提高复发性/难治性<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>患者的缓解率, objectTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, objectType=article, longId=207517, objectId=3e5020e5170d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021223/1614071826899_2110107.PNG, objectUrl=/article/show_article.do?id=3e5020e5170d, replyNumber=0, likeNumber=96, createdTime=2023-04-18, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=3e5020e5170d, moduleTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5020e5170d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796544, encodeId=42e11e9654427, content=<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=75, createdTime=2021-06-26, rootId=0, userName=ms49895894946433513521, userId=9e302500146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796545, encodeId=e9041e96545eb, content=<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a>, objectTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, objectType=article, longId=207517, objectId=3e5020e5170d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5020e5170d, replyNumber=0, likeNumber=58, createdTime=2021-10-17, rootId=0, userName=ms49895894946433513521, userId=9e302500146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5020e5170d, moduleTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5020e5170d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796543, encodeId=4a4b1e9654307, content=<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a>, objectTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, objectType=article, longId=193716, objectId=100b193e1677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100b193e1677, replyNumber=0, likeNumber=77, createdTime=2020-09-28, rootId=0, userName=ms49895894946433513521, userId=9e302500146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100b193e1677, moduleTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=100b193e1677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796542, encodeId=813c1e96542eb, content=<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a>, objectTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, objectType=article, longId=180400, objectId=2b0b180400c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0b180400c6, replyNumber=0, likeNumber=87, createdTime=2020-04-17, rootId=0, userName=ms49895894946433513521, userId=9e302500146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0b180400c6, moduleTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0b180400c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796541, encodeId=13fe1e96541fb, content=<a href='/topic/show?id=489c180659c' target=_blank style='color:#2F92EE;'>#Ublituximab#</a>, objectTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, objectType=article, longId=174977, objectId=d4a81e497768, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4a81e497768, replyNumber=0, likeNumber=73, createdTime=2019-11-13, rootId=0, userName=ms49895894946433513521, userId=9e302500146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4a81e497768, moduleTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4a81e497768)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ublituximab

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#依鲁替尼#加用#Ublituximab##乌妥昔单抗#可显著提高复发性/难治性#慢性淋巴细胞白血病#患者的缓解率

Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率

2023-04-18发表于香港

ms49895894946433513521 (审核中...)

前往app查看评论内容

#Ublituximab#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2021-06-26

ms49895894946433513521 (审核中...)

前往app查看评论内容

#Ublituximab#

Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率

2021-10-17

ms49895894946433513521 (审核中...)

前往app查看评论内容

#Ublituximab#

PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止

2020-09-28

ms49895894946433513521 (审核中...)

前往app查看评论内容

#Ublituximab#

Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估

2020-04-17

ms49895894946433513521 (审核中...)

前往app查看评论内容

#Ublituximab#

2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好

2019-11-13

科室
- - 订阅+
  - 更多科室
工具
服务